What is the current price and short-term target for INFE.PA stock?

INFE.PA stock trades at **€71.00** intraday on EURONEXT with a near-term Meyka target of **€74.29**, implying an upside near **4.63%** from the current price; traders should use tight stops because liquidity is low.

How does Compagnie Industrielle’s valuation look?

Valuation is moderate: EPS **6.35** and trailing PE around **11.18**, price-to-sales **0.33**, and price-to-book **3.33**; cash per share **€29.94** and low net debt support the balance sheet.

What are the main risks for an oversold-bounce trade on INFE.PA stock?

Primary risks are very low liquidity, unexpected contract delays, and parent-company moves; use a defined stop and limit size to manage gap or slippage risk during intraday trading.

How does Meyka AI rate INFE.PA?

Meyka AI rates INFE.PA **69.82/100** (Grade **B**, Suggestion **HOLD**), based on benchmark, sector, financials, key metrics, and forecasts; grades are informational and not financial advice.

EU Stocks

INFE.PA Compagnie Industrielle EURONEXT 10 Feb 2026: Oversold bounce to €74.29

ByDanny Kontos February 10, 2026February 10, 2026

INFE.PA stock is trading at €71.00 intraday on EURONEXT as we watch a potential oversold bounce after recent weakness versus the 50-day average of €75.04. Volume is thin today at 16.00 shares versus an average of 85.00, which magnifies short-term moves. Fundamentals remain solid: reported EPS is 6.35, and trailing PE sits near 11.18 on the latest quote. This setup gives traders a defined risk zone and a clear short-term target near €74.29.